Neogen   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Lansing MI United States (1982)
Status: No NME R&D (1982)

Organization Overview

First Clinical Trial
2024
NCT06107894
First Marketed Drug
2012
irbesartan (avapro)
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NeogenTC